BioWorld - Sunday, January 19, 2020

U.S.
%{topic} RSS Feed RSS

1-16-nevro-senza-omnia.png
J.P. Morgan Healthcare Conference

Nevro aims to dominate pain neurostimulation with Omnia to treat across frequencies

January 16, 2020
By Stacy Lawrence
No Comments
SAN FRANCISCO – After slowing growth starting in mid-2018 and a court battle with Boston Scientific Corp. that ended in a favorable resolution, 2019 was a much better year for pain neurostimulation player Nevro Corp., as it launched a major new product. So far, 2020 is looking up too. Its shares (NYSE:NVRO) gained 5% following a presentation at the J.P. Morgan (JPM) Healthcare Conference, where it preannounced 2019 revenues and offered 2020 guidance.
Read More
1-16-exact-sciences-cologuard.png
J.P. Morgan Healthcare Conference

Wall Street wonders where Exact Sciences is headed in wake of Genomic Health acquisition

January 16, 2020
By Stacy Lawrence
No Comments
SAN FRANCISCO – Investor confidence in Exact Sciences Corp. has started to stumble in recent months. The Madison, Wis.-based company’s valuation peaked at about $15.5 billion just a few short weeks after it announced that it would acquire Genomic Health Inc. in late July. Its market cap trajectory has been uneven since and took another hit when the company preannounced 2019 earnings at the J.P. Morgan (JPM) Healthcare Conference, falling to around $13.5 billion.
Read More
Gene therapy
J.P. Morgan Healthcare Conference

Population genetic studies set up for success, as they aim for health care and research results

January 15, 2020
By Stacy Lawrence
No Comments
SAN FRANCISCO – Major genetic research efforts designed to encompass millions of people globally have been setting up their infrastructure in recent years to serve both researchers and patients. This work is being done by major national initiatives, such as All of Us in the U.S. and Genomics England in the U.K., as well as by health care systems such as Intermountain and Kaiser.
Read More
Cancer-and-Cancer-immunotherapy.png
J.P. Morgan Healthcare Conference

Guardant embraces biopharma research, screening to maintain momentum

January 15, 2020
By Stacy Lawrence
No Comments
SAN FRANCISCO – Guardant Health Inc. has set the standard for liquid biopsy. That success has catapulted the Redwood City, Calif.-based company from an IPO in the fall of 2018 to a current valuation in excess of $7 billion. It has made its name – and much of its revenue – with its Guardant360 test, a molecular diagnostic test that assesses 74 cancer-related genes from the circulating tumor DNA to aid in designing the best treatment for advanced cancer patients with solid tumors.
Read More
Gavel-and-scales.png

Supreme Court passes on Athena patent case despite Solicitor General’s endorsement

January 14, 2020
By Mark McCarty
No Comments
The U.S. Supreme Court has declined to hear the case of Athena v. Mayo, which many hoped would ease the patent subject matter eligibility problem. This outcome leaves Congress and the Court of Appeals for the Federal Circuit as the only likely sources of resolution for the problem, but there is skepticism as to whether either of these parties is both willing and able to overcome the impasse.
Read More

Popular Stories

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe